Teva Pharmaceutical Industries (NYSE:TEVA) commences the U.S. commercial launch of its generic version of Ferring B.V.’s Euflexxa (1% sodium hyaluronate) for the treatment of pain associated with osteoarthritis of the knee in patients who have failed to adequately respond to non-drug therapy and simple painkillers (e.g., acetaminophen).
Shares are up 2% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.